Raymond James Financial’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$22.3M Buy
392,784
+23,378
+6% +$1.36M 0.01% 1456
2026
Q2
$21.5M Buy
369,406
+109,011
+42% +$5.92M 0.01% 1512
2026
Q1
$14.6M Buy
260,395
+74,544
+40% +$4.05M ﹤0.01% 1707
2025
Q4
$8.45M Sell
185,851
-3,442
-2% -$154K ﹤0.01% 2103
2025
Q3
$6.82M Sell
189,293
-110,289
-37% -$3.65M ﹤0.01% 2227
2025
Q2
$9.7M Buy
299,582
+6,448
+2% +$211K ﹤0.01% 1890
2025
Q1
$11.1M Buy
293,134
+28,430
+11% +$2.27M ﹤0.01% 1730
2024
Q4
$21.7M Buy
+264,704
New +$26.3M 0.01% 1246

Other funds holding PCVX

Raymond James Financial's PCVX Position: Q3 2026 in Review

Raymond James Financial increased its Vaxcyte (PCVX) stake by 6.3% in Q3 2026, buying an estimated $1.36M and bringing the position to 392,784 shares worth $22.3M. The position accounts for 0.01% of the portfolio, ranked #1456.

Raymond James Financial first reported a position in PCVX in Q4 2024 and has held it in 8 quarters since. 354 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Raymond James Financial held 392,784 shares of Vaxcyte worth $22.3M as of Q3 2026.
  • Raymond James Financial bought 23,378 Vaxcyte shares in Q3 2026, an estimated $1.36M.
  • Vaxcyte made up 0.01% of Raymond James Financial's portfolio in Q3 2026, its #1456 holding.
  • Raymond James Financial first reported a position in Vaxcyte in Q4 2024 and has held it in 8 quarters since.
  • 354 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.